Verastem 
Welcome,         Profile    Billing    Logout  
 6 Products   19 Diseases  6 Products   53 Trials   2535 News 
64 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avmapki (avutometinib) / Verastem
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group, Korean Gynecologic Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Checkmark Trial initiated for LGSOC and KRAS mutated NSCLC
Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC
Completed
2
90
Europe, US
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
08/23
12/23
CHAMELEON, NCT06394804: A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

Recruiting
2
20
US
Avutometinib, VS-6766, Defactinib, VS-6063, Letrozole
Memorial Sloan Kettering Cancer Center, Verastem, Inc.
Low-Grade Serous Ovarian Cancer
04/27
04/27
20P.1113, NCT04720417: Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

Active, not recruiting
2
13
US
Defactinib Hydrochloride, 1073160-26-5, Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-Hydrochloride (1:1), PF-04554878, VS-6063, Raf/MEK Inhibitor VS-6766, CH5126766, 946128-88-7, CH-5126766, CKI-27, R-7304, RG 7304, RG-7304, RO-5126766 FREE BASE, RO5126766, VS 6766, VS-6766, AVUTOMETINIB, Biopsy, BIOPSY_TYPE, Bx
Thomas Jefferson University, Verastem, Inc.
Metastatic Uveal Melanoma
04/24
01/25
NCT06495125: Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Recruiting
2
50
US
Avutometinib, CH-5126766, CH5126766, CKI-27, R-7304, Raf/MEK Inhibitor VS-6766, RG 7304, RG-7304, RG7304, RO5126766, VS 6766, VS-6766, VS6766, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Defactinib, PF-04554878, VS-6063, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
Emory University, National Cancer Institute (NCI)
Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
03/28
09/28
NCT06487221: Avutometinib and Defactinib in Diffuse Gastric Cancer

Recruiting
2
27
US
Avutometinib, VS6766, Defactinib, VS-6063
Ryan H. Moy, MD, PhD, Verastem Oncology
Gastric Cancer, Stomach Cancer
11/28
05/29
RAMP201J, NCT06682572: A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Recruiting
2
15
Japan
Avutometinib (VS-6766) + Defactinib (VS-6063)
Verastem, Inc., Japanese Gynecologic Oncology Group (JGOG)
Low Grade Serous Ovarian Cancer, Ovarian Cancer
12/25
10/27
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
NCT06369259: Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Recruiting
2
33
US
Defactinib, Cetuximab, ERBITUX, Avutometinib
M.D. Anderson Cancer Center
Advanced Colorectal Cancer
02/26
02/28
NCT05787561: A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

Recruiting
2
40
US
Avutometinib (VS-6766), Defactinib
Memorial Sloan Kettering Cancer Center, Verastem, Inc.
Mesonephric Gynecologic Cancer
03/26
03/26
NCT06007924: A Study of Avutometinib and Defactinib in People With Thyroid Cancer

Recruiting
2
30
US
Avutometinib, Defactinib
Memorial Sloan Kettering Cancer Center, Verastem, Inc.
Thyroid Cancer
08/27
08/27
DURAFAK, NCT05512208: A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

Recruiting
2
55
US
Avutometinib (VS-6766) + defactinib
University of Oklahoma, Verastem, Inc.
Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer, Cervical Cancer, Solid Tumor
12/27
12/29
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting
1/2
153
Europe, US
avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063
Verastem, Inc., Amgen
Non Small Cell Lung Cancer, KRAS Activating Mutation
09/25
04/27
DETERMINE, NCT06194929: Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Recruiting
1/2
33
US
Defactinib, Avutometinib, Encorafenib
University of Utah, Verastem, Inc.
Melanoma
01/28
01/30
NCT05200442: A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Suspended
1/2
53
US
VS-6766/avutometinib, Cetuximab, Erbitux, Pill Diary
University of Chicago, Verastem, Inc.
Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
08/25
08/25
NCT05375994: Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Active, not recruiting
1/2
85
US
avutometinib (VS-6766) and adagrasib, KRAS G12C Inhibitor, adagrasib, KRAZATI®
Verastem, Inc., Mirati Therapeutics Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
12/25
01/26
5G-RUBY, NCT06630260: Avutometinib and Defactinib in Malignant Brain Tumours

Recruiting
1/2
182
Europe
Avutometinib, VS-6766, Defactinib, Temozolomide, Temodal
Institute of Cancer Research, United Kingdom, Minderoo Foundation, Verastem, Inc., Royal Marsden NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Cancer Research UK, University of Cambridge
Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas
09/29
09/30
RAMP205, NCT05669482: Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Recruiting
1/2
40
US
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel, Gemzar, Abraxane
Verastem, Inc.
KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
08/26
08/27
NCT05608252: VS-6766+Abema+Fulv in Met HR+/HER- BC

Recruiting
1/2
63
US
VS-6766, Abemaciclib, Verzenio, Fulvestrant, Faslodex
Adrienne G. Waks, Verastem, Inc., Eli Lilly and Company
Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
12/27
12/28
FRAME, NCT03875820: Phase I Trial of Defactinib and VS-6766.

Checkmark Data from FRAME trial in combination with VS-6766 for Ovarian Cancer at ESMO 2021
Sep 2021 - Sep 2021: Data from FRAME trial in combination with VS-6766 for Ovarian Cancer at ESMO 2021
Checkmark Data from FRAME trial in combination with VS-6766 for Ovarian Cancer
Sep 2020 - Sep 2020: Data from FRAME trial in combination with VS-6766 for Ovarian Cancer
Checkmark Data from FRAME trial in combination with VS-6766 for solid tumors at AACR 2020
More
Active, not recruiting
1
87
Europe
VS-6766, RO5126766, CH5126766, Defactinib, VS-6063
Institute of Cancer Research, United Kingdom, Verastem, Inc.
NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma, Pancreatic Cancer
04/23
10/23
DDU RAF/MEK, NCT02407509: Phase I Trial of VS-6766 Alone and in Combination With Everolimus

Active, not recruiting
1
104
Europe
VS-6766, Everolimus
Royal Marsden NHS Foundation Trust, Institute of Cancer Research, United Kingdom, Chugai Pharmaceutical, Verastem, Inc.
Solid Tumours, Multiple Myeloma, Lung Cancer, Ovarian Cancer
06/25
06/25
NCT03681483: RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer

Completed
1
15
US
RO5126766, (CH5126766)
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Chugai Pharma USA
Advanced Non-small Cell Lung Cancer
07/24
07/24
NCT05798507: Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

Recruiting
1
12
US
Avutometinib, CH-5126766, CH5126766, CKI-27, R-7304, Raf/MEK Inhibitor VS-6766, RG 7304, RG-7304, RG7304, RO5126766, VS 6766, VS-6766, VS6766, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Defactinib
Emory University, National Cancer Institute (NCI), Verastem, Inc.
Glioblastoma, Recurrent Glioblastoma
10/25
10/26
NCT06104488: A Study of Avutometinib for People With Solid Tumor Cancers

Recruiting
1
24
US
Avutometinib
Memorial Sloan Kettering Cancer Center
Refractory Cancer, CNS Tumors, CNS Tumor, Adult, CNS Tumor, Childhood, MAP Kinase Family Gene Mutation, NF1, Plexiform Neurofibroma, Low-grade Glioma, Optic Pathway Gliomas, Neuroblastoma, Primary Brain Tumor, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, Central Nervous System Tumor
10/29
10/29
RAMP201J, jRCT2021240021: To confirm the efficacy of Avutometinib in combination with Defactinib in Japanese patients with LGSOC.

Recruiting
N/A
15
Japan
avutometinib (VS-6766) - Verastem, defactinib (VS-6063) - Verastem
Japan Clinical Research Operations K.K.
Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
 
 
Copiktra (duvelisib) / Secura Bio, Yakult Honsha
ChiCTR2300074621: Phase I/II Clinical Study of Mitoxantrone Hydrochloride Liposome Combined With Duvelisib in Patients With Relapsed/Refractory PTCL and NK/T

Not yet recruiting
4
72
 
Mitoxantrone hydrochloride liposome and Duvelisib; Mitoxantrone hydrochloride liposome and Duvelisib
Shandong Cancer Hospital; Shandong Cancer Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.
lymphoma
 
 
ChiCTR2300075967: Clinical study of DC-Gemox regimen in relapse or refractory AITL

Recruiting
4
20
 
Duvelisib and Chidamide in combination with CHOP regimen
The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Self-funded
Angioimmunoblastic T cell lymphoma
 
 
2013-002405-61: Study to assess the safety and efficacy of the study drug IPI-145/Duvelisib in Leukaemia patients compared with Ofatumumab

 
3
80
Europe
Duvelisib, ARZERRA, Duvelisib, Ofatumumab, Ofatumumab
Infinity Pharmaceuticals, Inc, Infinity Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
 
 
2013-003639-31: Study to assess the safety of the study drug IPI-145/Duvelisib or ofatumumab in leukemia patients

 
3
36
Europe
Duvelisib, ARZERRA, Duvelisib, L01XC10, OFATUMUMAB, OFATUMUMAB
Infinity Pharmaceuticals, Inc, Infinity Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
 
 
TERZO, NCT06522737: A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Recruiting
3
124
Europe
Duvelisib, Gemcitabine, Bendamustine
SecuraBio
Lymphoma
02/28
12/28
2016-000848-34: A follow-up study in patients with hematologic malignancies that are treated with experimental drug duvelisib Studio di follow up in pazienti con neoplasie ematologiche trattati con ii farmaco in sperimentazione duvelisib

Not yet recruiting
2
22
Europe
Duvelisib, [IPl-145], Capsule, hard
Verastem, INC, Verastem, Inc
Hematologic Malignancies Neoplasie Ematologiche, Hematologic Malignancies Neoplasie Ematologiche, Diseases [C] - Cancer [C04]
 
 
DYNAMO, NCT01882803 / 2013-004008-20: A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

Checkmark Approved for r/r CLL and refractory 3L follicular lymphoma
May 2021 - May 2021: Approved for r/r CLL and refractory 3L follicular lymphoma
Checkmark CHMP adopted a positive opinion for Copiktra as monotherapy for r/r 3L CLL & refractory 3L follicular lymphoma
Apr 2021 - Apr 2021: CHMP adopted a positive opinion for Copiktra as monotherapy for r/r 3L CLL & refractory 3L follicular lymphoma
Checkmark Submitted MAA in EU for CLL/SLL and FL
More
Completed
2
129
Europe, Canada, US, RoW
Duvelisib, Copiktra, IPI-145
SecuraBio
Indolent Non-Hodgkin Lymphoma
11/20
11/20
ChiCTR2000032427: Clinical study of Duvelisib in subjects with relapsed and refractory follicular lymphoma

Not yet recruiting
2
57
 
Duvelisib
Ruijin Hospital, Shanghai Jiaotong University School of Medicine; CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
relapsed and refractory follicular lymphoma
 
 
TEMPO, NCT04038359 / 2019-001381-14: A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma

Completed
2
103
Europe, US, RoW
Duvelisib, Copiktra, VS-0145, IPI-145
SecuraBio
Indolent Non-Hodgkin Lymphoma
07/23
07/23
PRIMO, NCT03372057 / 2019-001123-13: A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Checkmark Interim analysis data from trial for PTCL
Dec 2021 - Dec 2021: Interim analysis data from trial for PTCL
Checkmark In PRIMO study for the treatment of patients with r/r PTCL
Apr 2021 - Apr 2021: In PRIMO study for the treatment of patients with r/r PTCL
Checkmark From trial for relapsed/refractory peripheral T cell lymphoma
More
Completed
2
156
Europe, Japan, US
Duvelisib, IPI-145
SecuraBio
Peripheral T-cell Lymphoma
12/23
12/23
NCT05057247: Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Active, not recruiting
2
26
US
Duvelisib, VS-0145, Docetaxel, Taxotere
Glenn J. Hanna, Secura Bio, Inc.
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Cancer, Advanced Head and Neck Cancer, Advanced Head and Neck Squamous Cell Carcinoma
10/23
01/26
NCT05976997: Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Recruiting
2
36
RoW
Duvelisib, Chidamide
Liling Zhang, CSPC Ouyi Pharmaceutical Co., Ltd.
Newly Diagnosed Peripheral T-cell Lymphoma
12/23
12/24
NCT03961672: Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruiting
2
15
US
Duvelisib, 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one, Copiktra, INK-1197, IPI-145
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
07/23
06/25
A051902, NCT04803201: Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Recruiting
2
170
US
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral azacitidine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
06/26
06/26
NCT04331119: Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Active, not recruiting
2
17
US
Duvelisib, Copiktra, Peripheral blood draw
Washington University School of Medicine, SecuraBio
T-Cell Lymphoma
12/25
12/25
NCT02158091: A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Active, not recruiting
1/2
32
US
IPI-145, Fludarabine, Fludara, Cyclophosphamide, Cytoxan®, Neosar®, Rituximab, Rituxan
Dana-Farber Cancer Institute, Secura Bio, Inc.
Chronic Lymphocytic Leukemia
10/17
07/25
NCT03534323: Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Checkmark Data from P1/2 study in combination with venetoclax in r/r CLL at ASH 2019
Dec 2019 - Dec 2019: Data from P1/2 study in combination with venetoclax in r/r CLL at ASH 2019
Checkmark Data from P1 portion of P1/2 trial in combination with venetoclax for relapsed/refractory chronic lymphocytic leukemia at ASH 2019
Dec 2019 - Dec 2019: Data from P1 portion of P1/2 trial in combination with venetoclax for relapsed/refractory chronic lymphocytic leukemia at ASH 2019
Active, not recruiting
1/2
67
US
Duvelisib, IPI-145, Venetoclax, Venclexta
Dana-Farber Cancer Institute, Secura Bio, Inc.
Chronic Lymphocytic Leukemia, Richter Syndrome
12/24
07/26
NCT05508659: A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Not yet recruiting
1/2
128
NA
Duvelisib, COPIKTRA, SG001, Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumors
09/24
03/25
THEORY, NCT05675813: Genotype-guided Treatment in Newly Diagnosed PTCL

Recruiting
1/2
264
RoW
CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab, standard CHOP
Ruijin Hospital, The First Affiliated Hospital of Nanchang University, Peking University Third Hospital, Wuhan TongJi Hospital, West China Hospital, Nanfang Hospital, Southern Medical University, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of Soochow University, The Second Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital of Zhengzhou University, Beijing Tongren Hospital, Peking University People's Hospital, Sun Yat-sen University, The First Affiliated Hospital of Anhui Medical University, The First Hospital of Jilin University
Peripheral T Cell Lymphoma
07/26
07/28
NCT06810778: Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Not yet recruiting
1/2
12
US
Duvelisib, Venetoclax
Jonsson Comprehensive Cancer Center
T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory
06/30
06/31
NCT04688658: Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Active, not recruiting
1/2
13
US
Nivolumab, Opdivo, AG013736, Duvelisib, Copiktra
John Kirkwood, Secura Bio, Inc., Bristol-Myers Squibb
Unresectable Melanoma
02/24
12/28
jRCT2080224791: A Phase Ib Study of YHI-1702 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Completed
1
10
Japan
Copiktra (duvelisib) - Secura Bio, Yakult Honsha
Yakult Honsha Co., Ltd.
Chronic lymphocytic leukemia/small lymphocytic lymphoma
 
 
NCT03892044: Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Completed
1
7
US
Duvelisib, 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one, INK-1197, IPI-145, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
David Bond, MD
Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Richter Syndrome, Small Lymphocytic Lymphoma, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
02/24
02/24
NCT02783625: Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Checkmark In combination with romidepsin in r/r peripheral T-cell lymphoma
Dec 2018 - Dec 2018: In combination with romidepsin in r/r peripheral T-cell lymphoma
Hourglass May 2018 - May 2018 : P1 trial in relapsed/refractory T-cell lymphoma in combination with Velcade or Istodax
Active, not recruiting
1
114
US
Romidepsin, Bortezomib, duvelisib, IPI-145
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Stanford University
Lymphoma, Relapsed/Refractory T-cell Lymphomas
05/26
05/26
NCT04890236: Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Completed
1
4
US
Duvelisib, 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one, Copiktra, INK-1197, IPI-145, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T
Emory University, National Cancer Institute (NCI), Secura Bio, Inc., Novartis
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
03/24
09/24
NCT04652960: Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

Active, not recruiting
1
38
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Duvelisib, 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one, Copiktra, INK-1197, IPI 145, IPI-145, IPI145, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Punch Biopsy, BIOPSY, PUNCH, Punch Biopsy of Skin
National Cancer Institute (NCI)
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
12/25
11/27
NCT05044039: Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Active, not recruiting
1
42
US
Duvelisib
Washington University School of Medicine, SecuraBio, The Foundation for Barnes-Jewish Hospital, National Cancer Institute (NCI)
Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia
12/25
05/30
NCT07001384: A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Not yet recruiting
1
30
US
Alectinib, Duvelisib
Memorial Sloan Kettering Cancer Center, Genentech, Inc., Secura Bio, Inc.
Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma
06/31
06/31
NCT05010005: A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Recruiting
1
70
US
Ruxolitinib, Duvelisib
Memorial Sloan Kettering Cancer Center
T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
08/27
08/27
NCT05065866: Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Completed
1
14
US
BMS-986345, Oral Azacitidine, Duvelisib, Copiktra
H. Lee Moffitt Cancer Center and Research Institute, Secura Bio, Inc.
Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma, Lymphocytic Leukemia
01/24
04/24
ChiCTR2300074093: Prospective, single arm, single center study of Duvaliser combined with Cedarbamide in the treatment of newly treated peripheral T-cell lymphoma (PTCL)

Not yet recruiting
N/A
36
 
duvelisib+Chidamide
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, CSPC OUYI PHARMACEUTICAL CO., LTD.
peripheral T-cell lymphoma (PTCL)
 
 
NCT05923502: (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

Not yet recruiting
N/A
200
NA
Duvelisib, Copiktra
Ruijin Hospital
Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Richter Syndrome, Marginal Zone Lymphoma, Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma
11/27
11/27
Fakzynja (defactinib) / Verastem
NCT03727880: Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Active, not recruiting
2
36
US
Pembrolizumab, MK-3475, Keytruda, Defactinib
The University of Texas Health Science Center at San Antonio, Merck Sharp & Dohme LLC, Verastem, Inc.
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
07/25
07/25
EAY131-U, NCT04439331: Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Active, not recruiting
2
35
US
Defactinib Hydrochloride
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
11/20
12/25
NCI-MATCH, NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Checkmark Approved in combination with Trametinib for adult and pediatric patients with BRAF V600E solid tumors
Jan 2023 - Jan 2023: Approved in combination with Trametinib for adult and pediatric patients with BRAF V600E solid tumors
Checkmark Approved in combination with for Mekinist for BRAF V600E solid tumors
Jun 2022 - Jun 2022: Approved in combination with for Mekinist for BRAF V600E solid tumors
Checkmark Results from arm Z1D-a subprotocol of the NCI-MATCH study in mismatch repair-deficient non-colorectal cancers
More
Active, not recruiting
2
6452
US, RoW
Adavosertib, AZD 1775, AZD-1775, AZD1775, MK 1775, MK-1775, MK1775, Afatinib, BIBW 2992, BIBW-2992, BIBW2992, Afatinib Dimaleate, (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate), BIBW 2992MA2, BIBW2992 MA2, Gilotrif, Binimetinib, ARRY 162, ARRY 438162, ARRY-162, ARRY-438162, ARRY162, ARRY438162, MEK 162, MEK-162, MEK162, Mektovi, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capivasertib, AZD 5363, AZD-5363, AZD5363, Truqap, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Copanlisib, BAY 80 6946, BAY 80-6946, BAY 806946, BAY-80-6946, BAY806946, PI3K Inhibitor BAY 80-6946, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Crizotinib, Alkixen, Crizocent, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Dabrafenib, BRAF Inhibitor GSK2118436, GSK 2118436, GSK 2118436A, GSK-2118436, GSK-2118436A, GSK2118436, GSK2118436A, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Defactinib, PF-04554878, VS-6063, Defactinib Hydrochloride, Echocardiography Test, EC, Echocardiography, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Fexagratinib, ABSK-091, ABSK091, AZD4547, FGFR Inhibitor AZD4547, KB-74810, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Laboratory Biomarker Analysis, Larotrectinib, ARRY 470, LOXO 101, LOXO-101, LOXO101, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Osimertinib, AZD 9291, AZD-9291, AZD9291, Mereletinib, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, PD0332991, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, PI3K-beta Inhibitor GSK2636771, GSK-2636771, GSK2636771, Radiologic Examination, Radiologic Evaluation, Radiologic Exam, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228, Sunitinib Malate, SU 011248, SU 11248, SU-011248, SU-11248, SU011248, SU11248, sunitinib, Sutent, Taselisib, GDC-0032, RO5537381, Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO 132365, PRO-132365, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Ulixertinib, BVD-523, VRT752271, Vismodegib, Erivedge, GDC 0449, GDC-0449, GDC0449, Hedgehog Antagonist GDC-0449
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
12/25
12/25
NCT04331041: Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Active, not recruiting
2
42
US
Adaptive stereotactic body radiation therapy, Adaptive SBRT, Defactinib, VS-6063, PF-04554878, Tumor biopsy, Research blood draw
Washington University School of Medicine, National Cancer Institute (NCI), Verastem, Inc.
Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
09/25
04/27
2015-003928-31: FAK-PD1 - A Phase I/IIa Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients with Advanced Solid Malignancies.

Not yet recruiting
1/2
59
Europe
Defactinib (VS-6063), Pembrolizumab (MK-3475), VS-6063, MK-3475, Tablet, Powder for concentrate for solution for infusion, KEYTRUDA
NHS Greater Glasgow and Clyde, University Of Glasgow, , CRUK New Agents Committee, MSD, Verastem Inc
Advanced, incurable cancer with no remaining standard-of-care treatment options that are suitable. Or where pembrolizumab is a licensed treatment option at that line of therapy. In Phase I, this may be any solid cancer. In Phase II, this will be pancreatic cancer, non-small cell lung cancer (NSCLC) or mesothelioma., Incurable cancer with no remaining standard treatment options that they should have first. All cancer types in the first part, then just pancreatic, non-small cell lung and mesothelioma in the second., Diseases [C] - Cancer [C04]
 
 
ROCKIF, NCT03287271: Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Recruiting
1/2
90
US
VS-6063, defactinib, Paclitaxel, Taxol, Carboplatin, Paraplatin
Michael McHale, Verastem, Inc., Nine Girls Ask
Ovarian Cancer
04/25
04/26
CELESTIAL-MDS, NCT05636514: Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS

Recruiting
1
12
RoW
Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET, ASTX727, INQOVI, Defactinib, VS-6063
Clinical Hub for Interventional Research (CHOIR), The University of New South Wales, Australian National University
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
06/25
12/25
VS-5584 / Verastem
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avmapki (avutometinib) / Verastem
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group, Korean Gynecologic Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Checkmark Trial initiated for LGSOC and KRAS mutated NSCLC
Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC
Completed
2
90
Europe, US
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
08/23
12/23
CHAMELEON, NCT06394804: A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

Recruiting
2
20
US
Avutometinib, VS-6766, Defactinib, VS-6063, Letrozole
Memorial Sloan Kettering Cancer Center, Verastem, Inc.
Low-Grade Serous Ovarian Cancer
04/27
04/27
20P.1113, NCT04720417: Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

Active, not recruiting
2
13
US
Defactinib Hydrochloride, 1073160-26-5, Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-Hydrochloride (1:1), PF-04554878, VS-6063, Raf/MEK Inhibitor VS-6766, CH5126766, 946128-88-7, CH-5126766, CKI-27, R-7304, RG 7304, RG-7304, RO-5126766 FREE BASE, RO5126766, VS 6766, VS-6766, AVUTOMETINIB, Biopsy, BIOPSY_TYPE, Bx
Thomas Jefferson University, Verastem, Inc.
Metastatic Uveal Melanoma
04/24
01/25
NCT06495125: Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Recruiting
2
50
US
Avutometinib, CH-5126766, CH5126766, CKI-27, R-7304, Raf/MEK Inhibitor VS-6766, RG 7304, RG-7304, RG7304, RO5126766, VS 6766, VS-6766, VS6766, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Defactinib, PF-04554878, VS-6063, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
Emory University, National Cancer Institute (NCI)
Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
03/28
09/28
NCT06487221: Avutometinib and Defactinib in Diffuse Gastric Cancer

Recruiting
2
27
US
Avutometinib, VS6766, Defactinib, VS-6063
Ryan H. Moy, MD, PhD, Verastem Oncology
Gastric Cancer, Stomach Cancer
11/28
05/29
RAMP201J, NCT06682572: A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Recruiting
2
15
Japan
Avutometinib (VS-6766) + Defactinib (VS-6063)
Verastem, Inc., Japanese Gynecologic Oncology Group (JGOG)
Low Grade Serous Ovarian Cancer, Ovarian Cancer
12/25
10/27
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
NCT06369259: Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Recruiting
2
33
US
Defactinib, Cetuximab, ERBITUX, Avutometinib
M.D. Anderson Cancer Center
Advanced Colorectal Cancer
02/26
02/28
NCT05787561: A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

Recruiting
2
40
US
Avutometinib (VS-6766), Defactinib
Memorial Sloan Kettering Cancer Center, Verastem, Inc.
Mesonephric Gynecologic Cancer
03/26
03/26
NCT06007924: A Study of Avutometinib and Defactinib in People With Thyroid Cancer

Recruiting
2
30
US
Avutometinib, Defactinib
Memorial Sloan Kettering Cancer Center, Verastem, Inc.
Thyroid Cancer
08/27
08/27
DURAFAK, NCT05512208: A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

Recruiting
2
55
US
Avutometinib (VS-6766) + defactinib
University of Oklahoma, Verastem, Inc.
Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer, Cervical Cancer, Solid Tumor
12/27
12/29
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting
1/2
153
Europe, US
avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063
Verastem, Inc., Amgen
Non Small Cell Lung Cancer, KRAS Activating Mutation
09/25
04/27
DETERMINE, NCT06194929: Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Recruiting
1/2
33
US
Defactinib, Avutometinib, Encorafenib
University of Utah, Verastem, Inc.
Melanoma
01/28
01/30
NCT05200442: A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Suspended
1/2
53
US
VS-6766/avutometinib, Cetuximab, Erbitux, Pill Diary
University of Chicago, Verastem, Inc.
Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
08/25
08/25
NCT05375994: Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Active, not recruiting
1/2
85
US
avutometinib (VS-6766) and adagrasib, KRAS G12C Inhibitor, adagrasib, KRAZATI®
Verastem, Inc., Mirati Therapeutics Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
12/25
01/26
5G-RUBY, NCT06630260: Avutometinib and Defactinib in Malignant Brain Tumours

Recruiting
1/2
182
Europe
Avutometinib, VS-6766, Defactinib, Temozolomide, Temodal
Institute of Cancer Research, United Kingdom, Minderoo Foundation, Verastem, Inc., Royal Marsden NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Cancer Research UK, University of Cambridge
Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas
09/29
09/30
RAMP205, NCT05669482: Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Recruiting
1/2
40
US
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel, Gemzar, Abraxane
Verastem, Inc.
KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
08/26
08/27
NCT05608252: VS-6766+Abema+Fulv in Met HR+/HER- BC

Recruiting
1/2
63
US
VS-6766, Abemaciclib, Verzenio, Fulvestrant, Faslodex
Adrienne G. Waks, Verastem, Inc., Eli Lilly and Company
Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
12/27
12/28
FRAME, NCT03875820: Phase I Trial of Defactinib and VS-6766.

Checkmark Data from FRAME trial in combination with VS-6766 for Ovarian Cancer at ESMO 2021
Sep 2021 - Sep 2021: Data from FRAME trial in combination with VS-6766 for Ovarian Cancer at ESMO 2021
Checkmark Data from FRAME trial in combination with VS-6766 for Ovarian Cancer
Sep 2020 - Sep 2020: Data from FRAME trial in combination with VS-6766 for Ovarian Cancer
Checkmark Data from FRAME trial in combination with VS-6766 for solid tumors at AACR 2020
More
Active, not recruiting
1
87
Europe
VS-6766, RO5126766, CH5126766, Defactinib, VS-6063
Institute of Cancer Research, United Kingdom, Verastem, Inc.
NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma, Pancreatic Cancer
04/23
10/23
DDU RAF/MEK, NCT02407509: Phase I Trial of VS-6766 Alone and in Combination With Everolimus

Active, not recruiting
1
104
Europe
VS-6766, Everolimus
Royal Marsden NHS Foundation Trust, Institute of Cancer Research, United Kingdom, Chugai Pharmaceutical, Verastem, Inc.
Solid Tumours, Multiple Myeloma, Lung Cancer, Ovarian Cancer
06/25
06/25
NCT03681483: RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer

Completed
1
15
US
RO5126766, (CH5126766)
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Chugai Pharma USA
Advanced Non-small Cell Lung Cancer
07/24
07/24
NCT05798507: Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

Recruiting
1
12
US
Avutometinib, CH-5126766, CH5126766, CKI-27, R-7304, Raf/MEK Inhibitor VS-6766, RG 7304, RG-7304, RG7304, RO5126766, VS 6766, VS-6766, VS6766, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Defactinib
Emory University, National Cancer Institute (NCI), Verastem, Inc.
Glioblastoma, Recurrent Glioblastoma
10/25
10/26
NCT06104488: A Study of Avutometinib for People With Solid Tumor Cancers

Recruiting
1
24
US
Avutometinib
Memorial Sloan Kettering Cancer Center
Refractory Cancer, CNS Tumors, CNS Tumor, Adult, CNS Tumor, Childhood, MAP Kinase Family Gene Mutation, NF1, Plexiform Neurofibroma, Low-grade Glioma, Optic Pathway Gliomas, Neuroblastoma, Primary Brain Tumor, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, Central Nervous System Tumor
10/29
10/29
RAMP201J, jRCT2021240021: To confirm the efficacy of Avutometinib in combination with Defactinib in Japanese patients with LGSOC.

Recruiting
N/A
15
Japan
avutometinib (VS-6766) - Verastem, defactinib (VS-6063) - Verastem
Japan Clinical Research Operations K.K.
Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
 
 
Copiktra (duvelisib) / Secura Bio, Yakult Honsha
ChiCTR2300074621: Phase I/II Clinical Study of Mitoxantrone Hydrochloride Liposome Combined With Duvelisib in Patients With Relapsed/Refractory PTCL and NK/T

Not yet recruiting
4
72
 
Mitoxantrone hydrochloride liposome and Duvelisib; Mitoxantrone hydrochloride liposome and Duvelisib
Shandong Cancer Hospital; Shandong Cancer Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.
lymphoma
 
 
ChiCTR2300075967: Clinical study of DC-Gemox regimen in relapse or refractory AITL

Recruiting
4
20
 
Duvelisib and Chidamide in combination with CHOP regimen
The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Self-funded
Angioimmunoblastic T cell lymphoma
 
 
2013-002405-61: Study to assess the safety and efficacy of the study drug IPI-145/Duvelisib in Leukaemia patients compared with Ofatumumab

 
3
80
Europe
Duvelisib, ARZERRA, Duvelisib, Ofatumumab, Ofatumumab
Infinity Pharmaceuticals, Inc, Infinity Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
 
 
2013-003639-31: Study to assess the safety of the study drug IPI-145/Duvelisib or ofatumumab in leukemia patients

 
3
36
Europe
Duvelisib, ARZERRA, Duvelisib, L01XC10, OFATUMUMAB, OFATUMUMAB
Infinity Pharmaceuticals, Inc, Infinity Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
 
 
TERZO, NCT06522737: A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Recruiting
3
124
Europe
Duvelisib, Gemcitabine, Bendamustine
SecuraBio
Lymphoma
02/28
12/28
2016-000848-34: A follow-up study in patients with hematologic malignancies that are treated with experimental drug duvelisib Studio di follow up in pazienti con neoplasie ematologiche trattati con ii farmaco in sperimentazione duvelisib

Not yet recruiting
2
22
Europe
Duvelisib, [IPl-145], Capsule, hard
Verastem, INC, Verastem, Inc
Hematologic Malignancies Neoplasie Ematologiche, Hematologic Malignancies Neoplasie Ematologiche, Diseases [C] - Cancer [C04]
 
 
DYNAMO, NCT01882803 / 2013-004008-20: A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

Checkmark Approved for r/r CLL and refractory 3L follicular lymphoma
May 2021 - May 2021: Approved for r/r CLL and refractory 3L follicular lymphoma
Checkmark CHMP adopted a positive opinion for Copiktra as monotherapy for r/r 3L CLL & refractory 3L follicular lymphoma
Apr 2021 - Apr 2021: CHMP adopted a positive opinion for Copiktra as monotherapy for r/r 3L CLL & refractory 3L follicular lymphoma
Checkmark Submitted MAA in EU for CLL/SLL and FL
More
Completed
2
129
Europe, Canada, US, RoW
Duvelisib, Copiktra, IPI-145
SecuraBio
Indolent Non-Hodgkin Lymphoma
11/20
11/20
ChiCTR2000032427: Clinical study of Duvelisib in subjects with relapsed and refractory follicular lymphoma

Not yet recruiting
2
57
 
Duvelisib
Ruijin Hospital, Shanghai Jiaotong University School of Medicine; CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
relapsed and refractory follicular lymphoma
 
 
TEMPO, NCT04038359 / 2019-001381-14: A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma

Completed
2
103
Europe, US, RoW
Duvelisib, Copiktra, VS-0145, IPI-145
SecuraBio
Indolent Non-Hodgkin Lymphoma
07/23
07/23
PRIMO, NCT03372057 / 2019-001123-13: A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Checkmark Interim analysis data from trial for PTCL
Dec 2021 - Dec 2021: Interim analysis data from trial for PTCL
Checkmark In PRIMO study for the treatment of patients with r/r PTCL
Apr 2021 - Apr 2021: In PRIMO study for the treatment of patients with r/r PTCL
Checkmark From trial for relapsed/refractory peripheral T cell lymphoma
More
Completed
2
156
Europe, Japan, US
Duvelisib, IPI-145
SecuraBio
Peripheral T-cell Lymphoma
12/23
12/23
NCT05057247: Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Active, not recruiting
2
26
US
Duvelisib, VS-0145, Docetaxel, Taxotere
Glenn J. Hanna, Secura Bio, Inc.
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Cancer, Advanced Head and Neck Cancer, Advanced Head and Neck Squamous Cell Carcinoma
10/23
01/26
NCT05976997: Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Recruiting
2
36
RoW
Duvelisib, Chidamide
Liling Zhang, CSPC Ouyi Pharmaceutical Co., Ltd.
Newly Diagnosed Peripheral T-cell Lymphoma
12/23
12/24
NCT03961672: Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruiting
2
15
US
Duvelisib, 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one, Copiktra, INK-1197, IPI-145
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
07/23
06/25
A051902, NCT04803201: Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Recruiting
2
170
US
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral azacitidine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
06/26
06/26
NCT04331119: Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Active, not recruiting
2
17
US
Duvelisib, Copiktra, Peripheral blood draw
Washington University School of Medicine, SecuraBio
T-Cell Lymphoma
12/25
12/25
NCT02158091: A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Active, not recruiting
1/2
32
US
IPI-145, Fludarabine, Fludara, Cyclophosphamide, Cytoxan®, Neosar®, Rituximab, Rituxan
Dana-Farber Cancer Institute, Secura Bio, Inc.
Chronic Lymphocytic Leukemia
10/17
07/25
NCT03534323: Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Checkmark Data from P1/2 study in combination with venetoclax in r/r CLL at ASH 2019
Dec 2019 - Dec 2019: Data from P1/2 study in combination with venetoclax in r/r CLL at ASH 2019
Checkmark Data from P1 portion of P1/2 trial in combination with venetoclax for relapsed/refractory chronic lymphocytic leukemia at ASH 2019
Dec 2019 - Dec 2019: Data from P1 portion of P1/2 trial in combination with venetoclax for relapsed/refractory chronic lymphocytic leukemia at ASH 2019
Active, not recruiting
1/2
67
US
Duvelisib, IPI-145, Venetoclax, Venclexta
Dana-Farber Cancer Institute, Secura Bio, Inc.
Chronic Lymphocytic Leukemia, Richter Syndrome
12/24
07/26
NCT05508659: A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Not yet recruiting
1/2
128
NA
Duvelisib, COPIKTRA, SG001, Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumors
09/24
03/25
THEORY, NCT05675813: Genotype-guided Treatment in Newly Diagnosed PTCL

Recruiting
1/2
264
RoW
CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab, standard CHOP
Ruijin Hospital, The First Affiliated Hospital of Nanchang University, Peking University Third Hospital, Wuhan TongJi Hospital, West China Hospital, Nanfang Hospital, Southern Medical University, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of Soochow University, The Second Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital of Zhengzhou University, Beijing Tongren Hospital, Peking University People's Hospital, Sun Yat-sen University, The First Affiliated Hospital of Anhui Medical University, The First Hospital of Jilin University
Peripheral T Cell Lymphoma
07/26
07/28
NCT06810778: Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Not yet recruiting
1/2
12
US
Duvelisib, Venetoclax
Jonsson Comprehensive Cancer Center
T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory
06/30
06/31
NCT04688658: Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Active, not recruiting
1/2
13
US
Nivolumab, Opdivo, AG013736, Duvelisib, Copiktra
John Kirkwood, Secura Bio, Inc., Bristol-Myers Squibb
Unresectable Melanoma
02/24
12/28
jRCT2080224791: A Phase Ib Study of YHI-1702 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Completed
1
10
Japan
Copiktra (duvelisib) - Secura Bio, Yakult Honsha
Yakult Honsha Co., Ltd.
Chronic lymphocytic leukemia/small lymphocytic lymphoma
 
 
NCT03892044: Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Completed
1
7
US
Duvelisib, 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one, INK-1197, IPI-145, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
David Bond, MD
Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Richter Syndrome, Small Lymphocytic Lymphoma, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
02/24
02/24
NCT02783625: Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Checkmark In combination with romidepsin in r/r peripheral T-cell lymphoma
Dec 2018 - Dec 2018: In combination with romidepsin in r/r peripheral T-cell lymphoma
Hourglass May 2018 - May 2018 : P1 trial in relapsed/refractory T-cell lymphoma in combination with Velcade or Istodax
Active, not recruiting
1
114
US
Romidepsin, Bortezomib, duvelisib, IPI-145
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Stanford University
Lymphoma, Relapsed/Refractory T-cell Lymphomas
05/26
05/26
NCT04890236: Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Completed
1
4
US
Duvelisib, 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one, Copiktra, INK-1197, IPI-145, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T
Emory University, National Cancer Institute (NCI), Secura Bio, Inc., Novartis
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
03/24
09/24
NCT04652960: Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

Active, not recruiting
1
38
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Duvelisib, 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one, Copiktra, INK-1197, IPI 145, IPI-145, IPI145, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Punch Biopsy, BIOPSY, PUNCH, Punch Biopsy of Skin
National Cancer Institute (NCI)
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
12/25
11/27
NCT05044039: Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Active, not recruiting
1
42
US
Duvelisib
Washington University School of Medicine, SecuraBio, The Foundation for Barnes-Jewish Hospital, National Cancer Institute (NCI)
Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia
12/25
05/30
NCT07001384: A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Not yet recruiting
1
30
US
Alectinib, Duvelisib
Memorial Sloan Kettering Cancer Center, Genentech, Inc., Secura Bio, Inc.
Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma
06/31
06/31
NCT05010005: A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Recruiting
1
70
US
Ruxolitinib, Duvelisib
Memorial Sloan Kettering Cancer Center
T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
08/27
08/27
NCT05065866: Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Completed
1
14
US
BMS-986345, Oral Azacitidine, Duvelisib, Copiktra
H. Lee Moffitt Cancer Center and Research Institute, Secura Bio, Inc.
Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma, Lymphocytic Leukemia
01/24
04/24
ChiCTR2300074093: Prospective, single arm, single center study of Duvaliser combined with Cedarbamide in the treatment of newly treated peripheral T-cell lymphoma (PTCL)

Not yet recruiting
N/A
36
 
duvelisib+Chidamide
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, CSPC OUYI PHARMACEUTICAL CO., LTD.
peripheral T-cell lymphoma (PTCL)
 
 
NCT05923502: (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

Not yet recruiting
N/A
200
NA
Duvelisib, Copiktra
Ruijin Hospital
Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Richter Syndrome, Marginal Zone Lymphoma, Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma
11/27
11/27
Fakzynja (defactinib) / Verastem
NCT03727880: Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Active, not recruiting
2
36
US
Pembrolizumab, MK-3475, Keytruda, Defactinib
The University of Texas Health Science Center at San Antonio, Merck Sharp & Dohme LLC, Verastem, Inc.
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
07/25
07/25
EAY131-U, NCT04439331: Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Active, not recruiting
2
35
US
Defactinib Hydrochloride
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
11/20
12/25
NCI-MATCH, NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Checkmark Approved in combination with Trametinib for adult and pediatric patients with BRAF V600E solid tumors
Jan 2023 - Jan 2023: Approved in combination with Trametinib for adult and pediatric patients with BRAF V600E solid tumors
Checkmark Approved in combination with for Mekinist for BRAF V600E solid tumors
Jun 2022 - Jun 2022: Approved in combination with for Mekinist for BRAF V600E solid tumors
Checkmark Results from arm Z1D-a subprotocol of the NCI-MATCH study in mismatch repair-deficient non-colorectal cancers
More
Active, not recruiting
2
6452
US, RoW
Adavosertib, AZD 1775, AZD-1775, AZD1775, MK 1775, MK-1775, MK1775, Afatinib, BIBW 2992, BIBW-2992, BIBW2992, Afatinib Dimaleate, (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate), BIBW 2992MA2, BIBW2992 MA2, Gilotrif, Binimetinib, ARRY 162, ARRY 438162, ARRY-162, ARRY-438162, ARRY162, ARRY438162, MEK 162, MEK-162, MEK162, Mektovi, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capivasertib, AZD 5363, AZD-5363, AZD5363, Truqap, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Copanlisib, BAY 80 6946, BAY 80-6946, BAY 806946, BAY-80-6946, BAY806946, PI3K Inhibitor BAY 80-6946, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Crizotinib, Alkixen, Crizocent, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Dabrafenib, BRAF Inhibitor GSK2118436, GSK 2118436, GSK 2118436A, GSK-2118436, GSK-2118436A, GSK2118436, GSK2118436A, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Defactinib, PF-04554878, VS-6063, Defactinib Hydrochloride, Echocardiography Test, EC, Echocardiography, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Fexagratinib, ABSK-091, ABSK091, AZD4547, FGFR Inhibitor AZD4547, KB-74810, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Laboratory Biomarker Analysis, Larotrectinib, ARRY 470, LOXO 101, LOXO-101, LOXO101, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Osimertinib, AZD 9291, AZD-9291, AZD9291, Mereletinib, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, PD0332991, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, PI3K-beta Inhibitor GSK2636771, GSK-2636771, GSK2636771, Radiologic Examination, Radiologic Evaluation, Radiologic Exam, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228, Sunitinib Malate, SU 011248, SU 11248, SU-011248, SU-11248, SU011248, SU11248, sunitinib, Sutent, Taselisib, GDC-0032, RO5537381, Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO 132365, PRO-132365, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Ulixertinib, BVD-523, VRT752271, Vismodegib, Erivedge, GDC 0449, GDC-0449, GDC0449, Hedgehog Antagonist GDC-0449
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
12/25
12/25
NCT04331041: Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Active, not recruiting
2
42
US
Adaptive stereotactic body radiation therapy, Adaptive SBRT, Defactinib, VS-6063, PF-04554878, Tumor biopsy, Research blood draw
Washington University School of Medicine, National Cancer Institute (NCI), Verastem, Inc.
Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
09/25
04/27
2015-003928-31: FAK-PD1 - A Phase I/IIa Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients with Advanced Solid Malignancies.

Not yet recruiting
1/2
59
Europe
Defactinib (VS-6063), Pembrolizumab (MK-3475), VS-6063, MK-3475, Tablet, Powder for concentrate for solution for infusion, KEYTRUDA
NHS Greater Glasgow and Clyde, University Of Glasgow, , CRUK New Agents Committee, MSD, Verastem Inc
Advanced, incurable cancer with no remaining standard-of-care treatment options that are suitable. Or where pembrolizumab is a licensed treatment option at that line of therapy. In Phase I, this may be any solid cancer. In Phase II, this will be pancreatic cancer, non-small cell lung cancer (NSCLC) or mesothelioma., Incurable cancer with no remaining standard treatment options that they should have first. All cancer types in the first part, then just pancreatic, non-small cell lung and mesothelioma in the second., Diseases [C] - Cancer [C04]
 
 
ROCKIF, NCT03287271: Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Recruiting
1/2
90
US
VS-6063, defactinib, Paclitaxel, Taxol, Carboplatin, Paraplatin
Michael McHale, Verastem, Inc., Nine Girls Ask
Ovarian Cancer
04/25
04/26
CELESTIAL-MDS, NCT05636514: Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS

Recruiting
1
12
RoW
Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET, ASTX727, INQOVI, Defactinib, VS-6063
Clinical Hub for Interventional Research (CHOIR), The University of New South Wales, Australian National University
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
06/25
12/25
VS-5584 / Verastem
No trials found

Download Options